@article{435b1021a8d44db28b00db6e95650f69,
title = "A33scFV-cytosine deaminase: A recombinant protein construct for antibody-directed enzyme-prodrug therapy",
abstract = "A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.",
keywords = "A33 antibody, Antibody, Colon carcinoma, Directed enzyme-producing therapy (ADEPT), Recombinant fusion proteins, Tumour targeting",
author = "Deckert, {P. M.} and C. Renner and Cohen, {L. S.} and A. Jungbluth and G. Ritter and Joseph Bertino and Old, {L. J.} and S. Welt",
note = "Funding Information: The authors thank Dr Christoph Rader and Dr Carlos F. Barbas III of the Scripps Institute, La Jolla, California, for providing the A33scFv plasmid for their excellent advice in realizing this project and for critical review of the manuscript. This work has been sponsored by National Cancer Institute Grants No. CA-33049 and CA-08748 to SW, and by Deutsche Forschungsgemeinschaft Grant No. De602/1-1 and the US Army Breast Cancer Research Program Grant No. DAMD17-99-1-9370 to PMD.",
year = "2003",
month = mar,
day = "24",
doi = "10.1038/sj.bjc.6600751",
language = "English (US)",
volume = "88",
pages = "937--939",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",
}